LUNAR-2: TTFields, Pembrolizumab and Platinum Chemotherapy for mNSCLC
Research type
Research Study
Full title
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
IRAS ID
358347
Contact name
Sandra Gumy
Contact email
Sponsor organisation
Novocure GmbH
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 9 months, 10 days
Research summary
Worldwide, lung cancer is the leading cause of cancer death. Approximately 84% of patients with lung cancer have Non-Small Cell Lung Cancer and about 60% of them have stage IV by the time of diagnosis.
The combination chemotherapy regimens produce 1-year survival rates of 30-40% and are more efficacious than single agents. The treatment strategy has however changed considerably in recent years following the introduction of immunotherapy and the impressive clinical results with improved overall survival both in the first- and in the secondline setting.
Tumour Treating Fields (TTFields) are a non-invasive, restricted to a localised region of the body treatment for solid tumours that is well tolerated.
TTFields are delivered to the tumour site via a portable medical device that consists of a field generator and arrays that are placed on the patient’s skin.
TTFields target cancer cells via multipole mechanisms, disrupting processes important for cancer cells (e.g. division and movement), which can ultimately lead to cell death over time.
The purpose of this Study is to evaluate the effectiveness and safety of TTFields together with standard of care pembrolizumab and platinum-based chemotherapy.REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
25/NW/0298
Date of REC Opinion
5 Jan 2026
REC opinion
Further Information Favourable Opinion